These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 3130316)

  • 41. Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer.
    Paridaens R; Focan C; Michel J; Piccart M; Salamon E; Beauduin M; Closon MT; Tueni E; Vindevoghel A; Majois F
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S63-5. PubMed ID: 2112055
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna.
    Bokemeyer C; Schmoll HJ; Ludwig E; Harstrick A; Dunn T; Casper J
    Br J Cancer; 1994 May; 69(5):863-7. PubMed ID: 8180015
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CNS-side effects induced by Ifosfamide-Mesna in children with osteosarcomas.
    Delépine N; Taillard F; Desbois JG; Cornille H; Delépine G; Jasmin C
    Biomed Pharmacother; 1986; 40(5):173-5. PubMed ID: 3098318
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ifosfamide in combination chemotherapy for sarcomas and testicular carcinomas.
    Niederle N; Scheulen ME; Cremer M; Schütte J; Schmidt CG; Seeber S
    Cancer Treat Rev; 1983 Sep; 10 Suppl A():129-35. PubMed ID: 6627239
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of ifosfamide in paediatric cancer.
    Advani SH
    Aust N Z J Med; 1998 Jun; 28(3):410-3. PubMed ID: 9673760
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinoma.
    Turrill M; Spicer DV; Kelley AS; Herman RL; Russell CA; Muggia FM
    Cancer Invest; 1995; 13(2):160-4. PubMed ID: 7874569
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Clinical experiences with holoxan within the framework of sequential combination therapy (author's transl)].
    Hartwich G; Neidhardt B; Lutz H
    Med Klin; 1978 Sep; 73(36):1247-52. PubMed ID: 692477
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase II study of ifosfamide as a single drug for relapsed paediatric patients.
    Schwartzman E; Scopinaro M; Angueyra N
    Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S11-2. PubMed ID: 2503255
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration.
    Katz A; Epelman S; Anelli A; Gorender EF; Cruz SM; Oliveira RM; Marques LA
    J Cancer Res Clin Oncol; 1995; 121(2):128-31. PubMed ID: 7883776
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase II trial of ifosfamide/mesna in metastatic adult renal carcinoma.
    De Forges A; Droz JP; Ghosn M; Theodore C
    Cancer Treat Rep; 1987 Nov; 71(11):1103. PubMed ID: 3119203
    [No Abstract]   [Full Text] [Related]  

  • 51. Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 8552.
    Case DC; Anderson J; Ervin TJ; Gottlieb A
    Med Pediatr Oncol; 1988; 16(3):182-6. PubMed ID: 3132591
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Encephalopathy in ifosfamide-treated patients.
    Merimsky O; Reider-Groswasser I; Wigler N; Chaitchik S
    Acta Neurol Scand; 1992 Nov; 86(5):521-5. PubMed ID: 1481635
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase II study of ifosfamide in children with recurrent solid tumours.
    Pinkerton CR; Rogers H; James C; Bowman A; Barbor PR; Eden OB; Pritchard J
    Cancer Chemother Pharmacol; 1985; 15(3):258-62. PubMed ID: 4053269
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics.
    Brock N; Pohl J
    IARC Sci Publ; 1986; (78):269-79. PubMed ID: 3108156
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pattern of paediatric solid malignant tumours in southern Orissa.
    Panda BK; Dandapat MC; Parida N
    J Indian Med Assoc; 1989 Jun; 87(6):136-7. PubMed ID: 2584729
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro studies on interaction of 4-hydroperoxyifosfamide and 2-mercaptoethanesulphonate in malignant gliomas.
    Jäger AH; Bogdahn U; Apfel R; Pfeufer B; Dekant A
    J Cancer Res Clin Oncol; 1993; 119(12):721-6. PubMed ID: 8408185
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Clinical experiences with Holoxan in small cell carcinoma of the bronchus (author's transl)].
    Kokron O; Titscher R; Micksche M; Cerni C; Wrba H
    Osterr Z Onkol; 1977 Nov; 4(5-6):103-6. PubMed ID: 579654
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ifosfamide studies for primary or recurrent pediatric malignant solid tumors and leukemia.
    Pratt CB
    Semin Oncol; 1990 Apr; 17(2 Suppl 4):31-40. PubMed ID: 2185546
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro studies on drug interaction of ifosfamide and ACNU in primary and metastatic human brain tumours.
    Bogdahn U; Drenkard D; Lutz M; Apfel R; Behl C
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S157-63. PubMed ID: 1795006
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ifosfamide-induced acute kidney injury in a patient with leiomyosarcoma: A case report.
    Boskabadi J; Yousefi-Mazhin E; Salehifar E
    Cancer Rep (Hoboken); 2022 Oct; 5(10):e1666. PubMed ID: 35830327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.